Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

MLA

Prebet, Thomas, et al. “Outcome of Patients Treated for Myelodysplastic Syndromes without Deletion 5q after Failure of Lenalidomide Therapy.” Oncotarget, vol. 8, no. 23, June 2017, pp. 37866–74. EBSCOhost, https://doi.org/10.18632/oncotarget.15200.

APA

Prebet, T., Toma, A., Cluzeau, T., Sekeres, M. A., Vey, N., Park, S., Al Ali, N., Sugrue, M. M., Komrokji, R., Fenaux, P., & Gore, S. D. (2017). Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 8(23), 37866–37874. https://doi.org/10.18632/oncotarget.15200

Chicago

Prebet, Thomas, Andrea Toma, Thomas Cluzeau, Mikkael A Sekeres, Norbert Vey, Sophie Park, Najla Al Ali, et al. 2017. “Outcome of Patients Treated for Myelodysplastic Syndromes without Deletion 5q after Failure of Lenalidomide Therapy.” Oncotarget 8 (23): 37866–74. doi:10.18632/oncotarget.15200.